FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4223607911> ?p ?o ?g. }

• W4223607911 endingPage "1051" @default.
• W4223607911 startingPage "1037" @default.
• W4223607911 abstract "Research is ongoing to increase our understanding of how much a previous diagnosis of type 2 diabetes mellitus (T2DM) affects someone's risk of becoming seriously unwell following a COVID-19 infection. In this study we set out to determine the relative likelihood of death following COVID-19 infection in people with T2DM when compared to those without T2DM. This was conducted as an urban population study and based in the UK.Analysis of electronic health record data was performed relating to people living in the Greater Manchester conurbation (population 2.82 million) who had a recorded diagnosis of T2DM and subsequent COVID-19 confirmed infection. Each individual with T2DM (n = 13,807) was matched with three COVID-19-infected non-diabetes controls (n = 39,583). Data were extracted from the Greater Manchester Care Record (GMCR) database for the period 1 January 2020 to 30 June 2021. Social disadvantage was assessed through Townsend scores. Death rates were compared in people with T2DM to their respective non-diabetes controls; potential predictive factors influencing the relative likelihood of admission were ascertained using univariable and multivariable logistic regression.For individuals with T2DM, their mortality rate after a COVID-19 positive test was 7.7% vs 6.0% in matched controls; the relative risk (RR) of death was 1.28. From univariate analysis performed within the group of individuals with T2DM, the likelihood of death following a COVID-19 recorded infection was lower in people taking metformin, a sodium-glucose cotransporter 2 inhibitor (SGLT2i) or a glucagon-like peptide 1 (GLP-1) agonist. Estimated glomerular filtration rate (eGFR) and hypertension were associated with increased mortality and had odds ratios of 0.96 (95% confidence interval 0.96-0.97) and 1.92 (95% confidence interval 1.68-2.20), respectively. Likelihood of death following a COVID-19 infection was also higher in those people with a diagnosis of chronic obstructive pulmonary disease (COPD) or severe enduring mental illness but not with asthma, and in people taking aspirin/clopidogrel/insulin. Smoking in people with T2DM significantly increased mortality rate (odds ratio of 1.46; 95% confidence interval 1.29-1.65). In a combined analysis of patients with T2DM and controls, multiple regression modelling indicated that the factors independently relating to a higher likelihood of death (accounting for 26% of variance) were T2DM, age, male gender and social deprivation (higher Townsend score).Following confirmed infection with COVID-19 a number of factors are associated with mortality in individuals with T2DM. Prescription of metformin, SGLT2is or GLP-1 agonists and non-smoking status appeared to be associated with a reduced the risk of death for people with T2DM. Age, male sex and social disadvantage are associated with an increased risk of death." @default.
• W4223607911 created "2022-04-15" @default.
• W4223607911 creator A5009872155 @default.
• W4223607911 creator A5010330353 @default.
• W4223607911 creator A5016584868 @default.
• W4223607911 creator A5017804509 @default.
• W4223607911 creator A5018107888 @default.
• W4223607911 creator A5020263487 @default.
• W4223607911 creator A5023330203 @default.
• W4223607911 creator A5037988440 @default.
• W4223607911 creator A5047046246 @default.
• W4223607911 creator A5058092061 @default.
• W4223607911 creator A5059494163 @default.
• W4223607911 creator A5075760256 @default.
• W4223607911 creator A5083538986 @default.
• W4223607911 creator A5091085981 @default.
• W4223607911 date "2022-04-13" @default.
• W4223607911 modified "2023-10-17" @default.
• W4223607911 title "Mortality in People with Type 2 Diabetes Following SARS-CoV-2 Infection: A Population Level Analysis of Potential Risk Factors" @default.
• W4223607911 cites W2068689271 @default.
• W4223607911 cites W3022580747 @default.
• W4223607911 cites W3024471844 @default.
• W4223607911 cites W3025089998 @default.
• W4223607911 cites W3029158812 @default.
• W4223607911 cites W3029548865 @default.
• W4223607911 cites W3031921507 @default.
• W4223607911 cites W3031959493 @default.
• W4223607911 cites W3038474713 @default.
• W4223607911 cites W3039197864 @default.
• W4223607911 cites W3039401323 @default.
• W4223607911 cites W3039509428 @default.
• W4223607911 cites W3044905147 @default.
• W4223607911 cites W3046353513 @default.
• W4223607911 cites W3047144258 @default.
• W4223607911 cites W3048439205 @default.
• W4223607911 cites W3048704086 @default.
• W4223607911 cites W3085656164 @default.
• W4223607911 cites W3089153595 @default.
• W4223607911 cites W3094542430 @default.
• W4223607911 cites W3095822337 @default.
• W4223607911 cites W3103724197 @default.
• W4223607911 cites W3103861847 @default.
• W4223607911 cites W3126061642 @default.
• W4223607911 cites W3131544246 @default.
• W4223607911 cites W3143117373 @default.
• W4223607911 cites W3152097801 @default.
• W4223607911 cites W3157222910 @default.
• W4223607911 cites W3166670257 @default.
• W4223607911 cites W3174793429 @default.
• W4223607911 cites W3183241150 @default.
• W4223607911 cites W3201642119 @default.
• W4223607911 cites W4210642183 @default.
• W4223607911 cites W4248158302 @default.
• W4223607911 doi "https://doi.org/10.1007/s13300-022-01259-3" @default.
• W4223607911 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35416588" @default.
• W4223607911 hasPublicationYear "2022" @default.
• W4223607911 type Work @default.
• W4223607911 citedByCount "16" @default.
• W4223607911 countsByYear W42236079112021 @default.
• W4223607911 countsByYear W42236079112022 @default.
• W4223607911 countsByYear W42236079112023 @default.
• W4223607911 crossrefType "journal-article" @default.
• W4223607911 hasAuthorship W4223607911A5009872155 @default.
• W4223607911 hasAuthorship W4223607911A5010330353 @default.
• W4223607911 hasAuthorship W4223607911A5016584868 @default.
• W4223607911 hasAuthorship W4223607911A5017804509 @default.
• W4223607911 hasAuthorship W4223607911A5018107888 @default.
• W4223607911 hasAuthorship W4223607911A5020263487 @default.
• W4223607911 hasAuthorship W4223607911A5023330203 @default.
• W4223607911 hasAuthorship W4223607911A5037988440 @default.
• W4223607911 hasAuthorship W4223607911A5047046246 @default.
• W4223607911 hasAuthorship W4223607911A5058092061 @default.
• W4223607911 hasAuthorship W4223607911A5059494163 @default.
• W4223607911 hasAuthorship W4223607911A5075760256 @default.
• W4223607911 hasAuthorship W4223607911A5083538986 @default.
• W4223607911 hasAuthorship W4223607911A5091085981 @default.
• W4223607911 hasBestOaLocation W42236079111 @default.
• W4223607911 hasConcept C126322002 @default.
• W4223607911 hasConcept C134018914 @default.
• W4223607911 hasConcept C144024400 @default.
• W4223607911 hasConcept C149923435 @default.
• W4223607911 hasConcept C2777180221 @default.
• W4223607911 hasConcept C2908647359 @default.
• W4223607911 hasConcept C2910068830 @default.
• W4223607911 hasConcept C44249647 @default.
• W4223607911 hasConcept C555293320 @default.
• W4223607911 hasConcept C71924100 @default.
• W4223607911 hasConcept C74909509 @default.
• W4223607911 hasConcept C82789193 @default.
• W4223607911 hasConcept C99454951 @default.
• W4223607911 hasConceptScore W4223607911C126322002 @default.
• W4223607911 hasConceptScore W4223607911C134018914 @default.
• W4223607911 hasConceptScore W4223607911C144024400 @default.
• W4223607911 hasConceptScore W4223607911C149923435 @default.
• W4223607911 hasConceptScore W4223607911C2777180221 @default.
• W4223607911 hasConceptScore W4223607911C2908647359 @default.
• W4223607911 hasConceptScore W4223607911C2910068830 @default.
• W4223607911 hasConceptScore W4223607911C44249647 @default.

• next